Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data.

The drug finerenone significantly slows the decline in kidney function in patients with chronic kidney disease (CKD) who do ...

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves ...

A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging a ...

Biological differences exist between males and females in kidney structure and function, leading to sex heterogeneity in the presentation and outcomes of chronic kidney disease (CKD) and response to ...

Finerenone reduced kidney function decline and cardiovascular-kidney events in non-diabetic CKD. Find out more from the ...

By Siddhi Mahatole and Sriparna Roy June 4 (Reuters) - Otsuka Pharmaceutical said on Thursday its drug in a late-stage study preserved kidney function over 12 months in patients with a type of ...

Chemotherapy, while vital for fighting cancer, places a significant burden on the kidneys as they filter out these powerful ...

Your daily coffee may affect your kidneys in surprising ways, and new research is changing what experts thought.